Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Christensen, Anne F ^a,i   Sørensen, Grith L ^b   Hørslev Petersen, Kim ^c   Holmskov, Uffe ^b   Lindegaard, Hanne M ^a   Junker, Kirsten ^b   Hetland, Merete L ^d   Stengaard Pedersen, Kristian ^e   Jacobsen, Søren ^f   Lottenburger, Tine ^c   Ellingsen, Torkell ^e   Andersen, Lis S ^c   Hansen, Ib ^e   Skjødt, Henrik ^d   Pedersen, Jens K ^c   Lauridsen, Ulrik B ^d   Svendsen, Anders ^a   Tarp, Ulrik ^e   Pødenphant, Jan ^g   Vestergaard, Aage ^h   Jurik, Anne G ^e   Østergaard, Mikkel ^e   Junker, Peter ^a   more..

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Rheumatism Hospital   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f Rigshospitalet   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h HVIDOVRE HOSPITAL   (Denmark)

ⁱ Institute of Clinical Research   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; SURFACTANT PROTEIN D; METALLOTHIONEIN; MT2A PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR SIZE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVIAL FLUID; ADOLESCENT; AGED; ARTHROGRAPHY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; FEMALE; GENOTYPE; HEALTH STATUS; HUMANS; MALE; METALLOTHIONEIN; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; QUESTIONNAIRES; REFERENCE VALUES; YOUNG ADULT;

EID: 77957006756     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2948     Document Type: Article

References (51)

1. Arend WP. The innate immune system in rheumatoid arthritis. Arthritis Rheum 2001, 44:2224-2234. 10.1002/1529-0131(200110)44:10<2224::AID-ART384>3.0.CO;2-H, 11665962.
2. Garred P, Madsen HO, Marquart H, Hansen TM, Sørensen SF, Petersen J, Volck B, Svejgaard A, Graudal NA, Rudd PM, Dwek RA, Sim RB, Andersen V. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheumatol 2000, 27:26-34.
3. Saevarsdottir S, Vikingsdottir T, Vikingsson A, Manfredsdottir V, Geirsson AJ, Valdimarsson H. Low Mannose Binding Lectin Predicts Poor Prognosis in Patients with Early Rheumatoid Arthritis. A Prospective Study. J Rheumatol 2001, 28:728-734.
4. Graudal NA, Madsen HO, Tarp U, Svejgaard A, Jurik AG, Graudal HK, Garred P. The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2000, 43:515-521. 10.1002/1529-0131(200003)43:3<515::AID-ANR6>3.0.CO;2-T, 10728743.
5. Jacobsen S, Madsen HO, Klarlund M, Jensen T, Skjodt H, Jensen KE, Svejgaard A, Garred P, . TIRA Group The influence of mannose binding lectin polymorpisms on disease outcome in early polyarthritis. J Rheumatol 2001, 28:935-942. TIRA Group.
6. Hoegh SV, Lindegaard HM, Sorensen GL, Hoj A, Bendixen C, Junker P, Holmskov U. Circulating Surfactant Protein D is Decreased in Early Rheumatoid Arthritis: A 1-year Prospective Study. Scand J Immunol 2008, 67:71-76.
7. Holmskov U. Collectins and collectin receptors in innate immunity. APMIS Suppl 2000, 100:1-59.
8. Holmskov U, Thiel S, Jensenius JC. Collectins and ficolins: Humoral Lectins of the Innate Immune Defense. Annu Rev Immunol 2003, 21:547-578. 10.1146/annurev.immunol.21.120601.140954, 12524383.
9. Crouch E, Chang D, Rust K, Persson A, Heuser J. Recombinant pulmonary surfactant protein D. Post-translational modification and molecular assembly. J Biol Chem 1994, 269:15808-15813.
10. Bufler P, Schmidt B, Schikor D, Bauernfeind A, Crouch EC, Griese M. Surfactant Protein A and D Differently Regulate the Immune Response to Nonmucoid Pseudomonas aeruginosa and Its Lipopolysaccharide. Am J Respir Cell Mol Biol 2003, 28:249-256. 10.1165/rcmb.4896, 12540493.
11. Hartshorn KL, White MR, Tecle T, Tornoe I, Sorensen GL, Crouch EC, Holmskov U. Reduced influenza viral neutralizing activity of natural human trimers of surfactant protein D. Respir Res 2007, 8:9. 1797806, 17280604, 10.1186/1465-9921-8-9.
12. Hartshorn KL, Crouch E, White MR, Colamussi ML, Kakkanatt A, Tauber B, Shepherd V, Sastry KN. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol 1998, 274:L958-L969.
13. Leth-Larsen R, Garred P, Jensenius H, Meschi J, Hartshorn K, Madsen J, Tornoe I, Madsen HO, Sorensen G, Crouch E, Holmskov U. A common polymorphism in the SFTPD gene influences assembly, function, and concentration of surfactant protein D. J Immunol 2005, 174:1532-1538.
14. Crouch E, Parghi D, Kuan SF, Persson A. Surfactant protein D: subcellular localization in nonciliated bronchiolar epithelial cells. Am J Physiol 1992, 263:L60-L66.
15. Stahlman MT, Gray ME, Hull WM, Whitsett JA. Immunolocalization of surfactant Protein-D (SP-D) in human fetal, newborn, and adult tissues. J Histochem Cytochem 2002, 50:651-660.
16. Madsen J, Kliem A, Tornoe I, Skjodt K, Koch C, Holmskov U. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J Immunol 2000, 164:5866-5870.
17. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995, 152:1860-1866.
18. Kankavi O. Increased expression of surfactant protein A and D in rheumatoid arthritic synovial fluid. Croat Med J 2006, 47:155-161. 2080374, 16489709.
19. Leth-Larsen R, Nordenbaek C, Tornoe I, Moeller V, Schlosser A, Koch C, Teisner B, Junker P, Holmskov U. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia. Clin Immunol 2003, 108:29-37. 10.1016/S1521-6616(03)00042-1, 12865068.
20. Nagae H, Takahashi H, Kuroki Y, Honda Y, Nagata A, Ogasawara Y, Abe S, Akino T. Enzyme-linked immunosorbent assay using F(ab')2 fragment for the detection of human pulmonary surfactant protein D in sera. Clin Chim Acta 1997, 266:157-171. 10.1016/S0009-8981(97)00124-1, 9437544.
21. Ni M, Evans DJ, Hawgood S, Anders EM, Sack RA, Fleiszig SMJ. Surfactant protein D is present in human tear fluid and the cornea and inhibits epithelial cell invasion by pseudomonas aeruginosa. Infect Immun 2005, 73:2147-2156. 1087391, 15784557, 10.1128/IAI.73.4.2147-2156.2005.
22. Sorensen GL, Hjelmborg J, Kyvik KO, Fenger M, Hoj A, Bendixen C, Sorensen T, Holmskov U. Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1010-L1017. 10.1152/ajplung.00487.2005, 16361352.
23. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, Pødenphant J, Hansen G, Lindegaard H, de Carvalho A, Østergaard M, Hørslev-Petersen K, . the Cimestra Study Group Combination treatment with methotrexate, ciclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis. Arthritis Rheum 2006, 54:1401-1409. 10.1002/art.21796, 16645967, the Cimestra Study Group.
24. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjodt H, Lauridsen UB, Ellingsen T, Hansen G, Lindegaard H, Vestergaard A, Jurik AG, Ostergaard M, Horslev-Petersen K. Aggressive combination therapy with intraarticular glucocorticoid injections and conventional DMARDs in early rheumatoid arthritis Two Year Clinical and Radiographic Results From The CIMESTRA Study. Ann Rheum Dis 2008, 67:815-822. 10.1136/ard.2007.076307, 17878209.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
26. Thorsen H, Hansen TM, Mckenna SP, Sørensen SF, Whalley D. Adaption into Danish of the stanford health assessment questionnaire (HAQ) and the rheumatoid arthritis quality of life scale (RaQol). Scand J Rheumatol 2001, 30:103-109. 10.1080/03009740151095402, 11324786.
27. Prevoo MLL, van 'T Hof MA, Kuper HH, van Leeuwen MA, Putte LBA, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
28. Høier-Madsen M, Nielsen LP, Møller S. Determination of IgM rheumatoid factors by enzyme-linked immunosorbent assay (ELISA). Ugeskr Laeger 1986, 148:2018-2021.
29. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S. Meta-analysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis. Ann Intern Med 2007, 146:797-808.
30. Vasiliauskiene L, Wiik A, Hoier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60:459-466. 1753650, 11302867, 10.1136/ard.60.5.459.
31. Heijde D. How to read radiographs according to Sharp/van der Heijde method. J Rheumatol 2000, 27:261-263.
32. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko M, Moreland LW, Weaver AL, Markenson J, Finck BK. A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. N Engl J Med 2000, 343:1586-1593. 10.1056/NEJM200011303432201, 11096165.
33. Hetland M, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik A, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjodt H, Pedersen J, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard HM, Christensen AF, Vallo J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M, . CIMESTRA study group MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA). Ann Rheum Dis 2009, 68:384-390. 10.1136/ard.2007.076307, 17878209, CIMESTRA study group.
34. Kimura A, Sasazuki T. Eleventh International Histocompatibility workshop. HLA 1991 1992, Oxford: Oxford University Press, Tsuji K, Aizawa M, Sasazuki M.
35. Heidinger K, Konig IR, Bohnert A, Kleinsteiber A, Hilgendorff A, Gortner L, Ziegler A, Chakraborty T, Bein G. Polymorphisms in the human surfactant protein-D (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced. Immunogenetics 2005, 57:1-7. 10.1007/s00251-005-0775-5, 15700120.
36. Palaniyar N, Clark H, Nadesalingam J, Hawgood S, Reid KB. Surfactant protein d binds genomic DNA and apoptotic cells, and enhances their clearance,in vivo. Ann NY Acad Sci 2003, 1010:471-475. 10.1196/annals.1299.085, 15033772.
37. Palaniyar N, Nadesalingam J, Clark H, Shih MJ, Dodds AW, Reid KB. Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin. J Biol Chem 2004, 279:N32728-32736. 10.1074/jbc.M403763200.
38. Liu G, Wu C, Wu Y, Zhao Y. Phagocytosis of apoptotic cells and immune regulation. Scand J Immunol 2006, 64:1-9. 10.1111/j.1365-3083.2006.01771.x, 16784485.
39. Palaniyar N, Clark H, Nadesalingam J, Shih MJ, Hawgood S, Reid KB. Innate immune collectin surfactant protein D enhances the clearance of DNA by macrophages and minimizes anti-DNA antibody generation. J Immunol 2005, 174:I7352-7358.
40. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE. Role of Surfactant Proteins A, D, and C1q in the Clearance of Apoptotic Cells In Vivo and In Vitro: Calreticulin and CD91 as a Common Collectin Receptor Complex. J Immunol 2002, 169:3978-3986.
41. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission. Arthritis Rheum 2006, 54:3761-3773. 10.1002/art.22190, 17133543.
42. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical examination and continued structural detoriation in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958-2967. 10.1002/art.23945, 18821687.
43. Kushner I, Somerville JA. Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arthritis Rheum 1971, 14:560-570. 10.1002/art.1780140503, 4106176.
44. Pejovic M, Stankovic A, Mitrovic DR. Determination of the apparent synovial permeability in the knee joint of patients suffering from osteoarthritis and rheumatoid arthritis. Br J Rheumatol 1995, 34:520-524. 10.1093/rheumatology/34.6.520, 7543347.
45. Simkin PA, Pizzorno JE. Synovial permeability in rheumatoid arthritis. Arthritis Rheum 1979, 22:689-696. 10.1002/art.1780220701, 454497.
46. Sorensen GL, Hoegh SV, Leth-Larsen R, Thomsen TH, Floridon C, Smith K, Kejling K, Tornoe I, Crouch EC, Holmskov U. Multimeric and trimeric subunit SP-D are inconvertible structures with distinct ligand interaction. Mol Immunol 2009, 10.1016/j.molimm.2009.06.005.
47. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM. By binding SIRP[alpha] or Calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003, 115:13-23. 10.1016/S0092-8674(03)00758-X, 14531999.
48. Guo CJ, Atochina-Vasserman EN, Abramova E, Foley JP, Zaman A, Crouch E, Beers MF, Savani RC, Gow AJ. S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol 2008, 6:e266. 2581630, 19007302, 10.1371/journal.pbio.0060266.
49. Schett G, Zwerina J, Firestein GS. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008, 67:909-916. 2754165, 17827184, 10.1136/ard.2007.074278.
50. Hermans CEDR, Bernard ALFR. Lung epithelium-specific proteins. characteristics and potential applications as markers. Am J Respir Crit Care Med 1999, 159:646-678.
51. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L, . the EIRA study group A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46. 10.1002/art.21575, 16385494, the EIRA study group.